Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 2

Sponsor Class

OTHER 2NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 2Lymphoid 2CNS 2Other hematologic neoplasm 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Glioma 2Brain Neoplasms 2Oligodendroglioma 1Neoplasms 1Glioblastoma 1Astrocytoma 1

Interventions

Temozolomide 400Radiotherapy 239Bevacizumab 185Magnetic Resonance Spectroscopy 168Radiosurgery 142Cyclophosphamide 95Irinotecan 79Carboplatin 79Etoposide 78Radiation 76pembrolizumab 70Nivolumab 59Surgical Procedures, Operative 57Filgrastim 56Specimen Handling 53Cisplatin 50Blood Specimen Collection 46Topotecan 45Vincristine 43Melphalan 38Radiotherapy, Intensity-Modulated 36Pemetrexed 36Lomustine 36Ipilimumab 36Everolimus 35Magnetic Resonance Imaging 34Erlotinib Hydrochloride 34Drug Therapy 34Surveys and Questionnaires 33sargramostim 30

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER × perifosine × CNS × Clear all
NCT02238496 2023-05-25

Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas

Columbia University

Phase 1 Completed
10 enrolled
CNS

Astrocytoma, Brain Neoplasms, Glioblastoma, Glioma, Oligodendroglioma

NCT00590954 2020-10-19

Clinical and Molecular-Metabolic Phase II Trial of Perifosine for Recurrent/Progressive Malignant Gliomas

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
32 enrolled 8 charts
CNS

Brain Neoplasms, Glioma, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡